P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL‐DEX, AND REAL‐WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
Mol, Isha, Hu, Yannan, Cappelleri, Joseph, Chu, Haitao, Aydin, Didem, Hlavacek, Patrick
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
A matching-adjusted indirect treatment comparison of elranatamab in patients with triple-class exposed relapsed/refractory multiple myeloma: Comparisons with belantamab mafodotin, selinexor plus dexamethasone, and real-world physician’s choice of treatment
Hlavacek, Patrick, Mol, Isha, Hu, Yannan, Cappelleri, Joseph C., Chu, Haitao, Aydin, Didem
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
Mol, Isha, Hu, Yannan, LeBlanc, Thomas W, Cappelleri, Joseph C, Chu, Haitao, Nador, Guido, Aydin, Didem, Schepart, Alex, Hlavacek, Patrick
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
Mol, Isha, Hu, Yannan, LeBlanc, Thomas W, Cappelleri, Joseph C, Chu, Haitao, Nador, Guido, Aydin, Didem, Schepart, Alex, Hlavacek, Patrick
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma
Mol, Isha, Hu, Yannan, LeBlanc, Thomas W, Cappelleri, Joseph C, Chu, Haitao, Nador, Guido, Aydin, Didem, Schepart, Alex, Hlavacek, Patrick
Published in Current medical research and opinion (01.02.2024)
Published in Current medical research and opinion (01.02.2024)
Get more information
Journal Article
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
Mol, Isha, Hu, Yannan, LeBlanc, Thomas W, Cappelleri, Joseph C, Chu, Haitao, Nador, Guido, Aydin, Didem, Schepart, Alex, Hlavacek, Patrick
Published in Leukemia & lymphoma (01.05.2024)
Published in Leukemia & lymphoma (01.05.2024)
Get more information
Journal Article
A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment Among Patients with Triple-Class Exposed/Refractory Multiple Myeloma in Canada
Mol, Isha, Hu, Yannan, Fanton-Aita, Fiorella, On, Phu Vinh, Gonzalez, Hicham, LeBlanc, Richard, Reece, Donna, Su, Jiandong, Gul, Engin, Visram, Alissa, Cappelleri, Joseph C, Chu, Haitao, Nador, Guido, Hlavacek, Patrick
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article